Morning Briefing
Summaries of health policy coverage from major news organizations
American Red Cross Limits Type O Blood Distribution Amid Supply Crisis
New Hampshire Public Radio: The American Red Cross Is Limiting Distribution Of Type O Blood Amid Shortage
The national blood shortage that began earlier in the year has now become a blood crisis, meaning there’s a critical depletion in blood supply across the country. The American Red Cross is asking for donors of all blood types. (Richardson, 8/10)
In other pharma and tech updates —
Stat: In Surprise Move, FDA Rejects Cancer Drug Expected To Rival Novartis Therapy
The Food and Drug Administration has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis. (DeAngelis, 8/10)
Bloomberg: Hims & Hers Plans To Offer Some Allowed Peptides Before Year-End
Hims & Hers Health Inc. plans to jump into the peptides market before the end of the year, with executives seeing opportunity to seize on a booming corner of the health industry. The telehealth company said Monday that it’s preparing to sell already allowed popular compounds including sermorelin and glutathione, which patients seek out for wellness and longevity benefits despite limited clinical evidence. (Ambaye and Muller, 8/10)
Stat: Sionna’s Experimental Cystic Fibrosis Pill Falls Flat In Mid-Stage Trial
Sionna Therapeutics said Monday that its experimental pill for cystic fibrosis did not show any benefit when added onto Vertex Pharmaceuticals’ Trikafta in a Phase 2 trial. (Mast, 8/10)
Stat: China Tightens Reins On Clinical Trials, As U.S. Tries To Replicate Its Rival’s Speed
For years, U.S. scientists and biotech companies have watched warily as China has made strides onto the global stage, overtaking them in research spending, patent applications, and clinical trials. (Yang, 8/10)
